51264-14-3 | N-(4-(Acridin-9-ylamino)-3-methoxyphenyl)methanesulfonamide

Packsize	Purity	Availability	Price	Discounted Price
5mg	98%	in stock	$60.00	$42.00
10mg	98%	in stock	$78.00	$54.00
25mg	98%	in stock	$156.00	$109.00
50mg	98%	in stock	$212.00	$148.00
100mg	98%	in stock	$279.00	$196.00
200mg	98%	in stock	$427.00	$299.00
500mg	98%	in stock	$797.00	$558.00
1g	98%	in stock	$1,241.00	$869.00

Description

• Catalog Number: AI51509
• Chemical Name: N-(4-(Acridin-9-ylamino)-3-methoxyphenyl)methanesulfonamide
• CAS Number: 51264-14-3
• Molecular Formula: C21H19N3O3S
• Molecular Weight: 393.4589
• MDL Number: MFCD00242748
• SMILES: COc1cc(ccc1Nc1c2ccccc2nc2c1cccc2)NS(=O)(=O)C
• NSC Number: 249992

Computed Properties

• Complexity: 601
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 28
• Hydrogen Bond Acceptor Count: 6
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 5
• XLogP3: 4

Literature

• Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs.

  Toxicological sciences : an official journal of the Society of Toxicology 20150601

• New derivatives of 11-methyl-6-[2-(dimethylamino)ethyl]-6H-indolo[2,3-b]quinoline as cytotoxic DNA topoisomerase II inhibitors.

  Bioorganic & medicinal chemistry letters 20121001

• Docking studies, synthesis, characterization of some novel oxazine substituted 9-anilinoacridine derivatives and evaluation for their antioxidant and anticancer activities as topoisomerase II inhibitors.

  European journal of medicinal chemistry 20121001

• Assessment of amsacrine binding with DNA using UV-visible, circular dichroism and Raman spectroscopic techniques.

  Journal of photochemistry and photobiology. B, Biology 20120903

• Dental methacrylates may exert genotoxic effects via the oxidative induction of DNA double strand breaks and the inhibition of their repair.

  Molecular biology reports 20120701

• Polymer conjugates of acridine-type anticancer drugs with pH-controlled activation.

  Bioorganic & medicinal chemistry 20120701

• Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.

  Annals of hematology 20120601

• Imidazonaphthyridine systems (part 2): Functionalization of the phenyl ring linked to the pyridine pharmacophore and its replacement by a pyridinone ring produces intriguing differences in cytocidal activity.

  European journal of medicinal chemistry 20120601

• A novel tetrahydrobenzoangelicin with dark and photo biological activity.

  Bioorganic & medicinal chemistry 20120601

• Synthesis and cytotoxic activity of new acridine-thiazolidine derivatives.

  Bioorganic & medicinal chemistry 20120601

• Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120301

• Amsacrine as a topoisomerase II poison: importance of drug-DNA interactions.

  Biochemistry 20120227

• 2-hydroxylethyl methacrylate (HEMA), a tooth restoration component, exerts its genotoxic effects in human gingival fibroblasts trough methacrylic acid, an immediate product of its degradation.

  Molecular biology reports 20120201

• AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.

  Cancer 20120201

• Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study.

  Bone marrow transplantation 20120101

• Synthesis, Crystal Structure, and DNA-Binding Studies of a Nickel(II) Complex with the Bis(2-benzimidazolymethyl)amine Ligand.

  Bioinorganic chemistry and applications 20120101

• Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation.

  Journal of experimental & clinical cancer research : CR 20120101

• [Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transplantation].

  Vnitrni lekarstvi 20120101

• Synthesis and biological activities of a 3'-azido analogue of Doxorubicin against drug-resistant cancer cells.

  International journal of molecular sciences 20120101

• Acridine: a versatile heterocyclic nucleus.

  Acta poloniae pharmaceutica 20120101

• Gene transfection enhanced by ultrasound exposure combined with drug treatment guided by gene chip analysis.

  International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 20120101

• The cadmium-mercaptoacetic acid complex contributes to the genotoxicity of mercaptoacetic acid-coated CdSe-core quantum dots.

  International journal of nanomedicine 20120101

• Modification of polyethylene glycol onto solid lipid nanoparticles encapsulating a novel chemotherapeutic agent (PK-L4) to enhance solubility for injection delivery.

  International journal of nanomedicine 20120101

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Phosphorylation and stabilization of topoisomerase IIα protein by p38γ mitogen-activated protein kinase sensitize breast cancer cells to its poisons.

  The Journal of biological chemistry 20111014

• Poor-risk cytogenetics may be associated with inferior outcome after fludarabine, cytarabine, and amsacrine reduced intensity conditioning in patients with high-risk acute myeloid leukemia.

  Leukemia & lymphoma 20111001

• Identifying compound-target associations by combining bioactivity profile similarity search and public databases mining.

  Journal of chemical information and modeling 20110926

• Cytotoxicity and genotoxicity of capecitabine in head and neck cancer and normal cells.

  Molecular biology reports 20110801

• A validated stability-indicating RP-HPLC assay method for Amsacrine and its related substances.

  Journal of chromatographic science 20110801

• Discovery of 4-anilinofuro[2,3-b]quinoline derivatives as selective and orally active compounds against non-small-cell lung cancers.

  Journal of medicinal chemistry 20110714

• Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110701

• Palladium-mediated intracellular chemistry.

  Nature chemistry 20110301

• Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110201

• Benzoquinazoline derivatives as new agents affecting DNA processing.

  Bioorganic & medicinal chemistry 20110201

• Myeloperoxidase-derived oxidation: mechanisms of biological damage and its prevention.

  Journal of clinical biochemistry and nutrition 20110101

• The impact of the C-terminal domain on the interaction of human DNA topoisomerase II α and β with DNA.

  PloS one 20110101

• Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers.

  Cell communication and signaling : CCS 20110101

• Review of cardiotoxicity in pediatric cancer patients: during and after therapy.

  Cardiology research and practice 20110101

• Acridine and acridinones: old and new structures with antimalarial activity.

  The open medicinal chemistry journal 20110101

• Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs).

  PloS one 20110101

• Drug therapy for hereditary cancers.

  Hereditary cancer in clinical practice 20110101

• An integrated Drosophila model system reveals unique properties for F14512, a novel polyamine-containing anticancer drug that targets topoisomerase II.

  PloS one 20110101

• Intracellular trafficking as a determinant of AS-DACA cytotoxicity in rhabdomyosarcoma cells.

  BMC cell biology 20110101

• Large Genomic Deletions in CACNA1A Cause Episodic Ataxia Type 2.

  Frontiers in neurology 20110101

• Synthesis, Crystal Structure, and Spectra Properties of the Cadmium (II) Complex with Bis(N-allylbenzimidazol-2-ylmethyl)benzylamine.

  Bioinorganic chemistry and applications 20110101

• Synthesis and characterization of the ligand based on benzimidazole and its copper complex: DNA binding and antioxidant activity.

  Bioinorganic chemistry and applications 20110101

• Development of derivatives of 3, 3'-diindolylmethane as potent Leishmania donovani bi-subunit topoisomerase IB poisons.

  PloS one 20110101

• Effect of dietary, social, and lifestyle determinants of accelerated aging and its common clinical presentation: A survey study.

  Ayu 20110101

• Study of Vaikalyakara Marma with special reference to Kurpara Marma.

  Ayu 20110101

• Structural modifications on the phenazine N,N'-dioxide-scaffold looking for new selective hypoxic cytotoxins.

  European journal of medicinal chemistry 20101101

• Pyridazinopsoralens of wide chemotherapeutic interest.

  Bioorganic & medicinal chemistry 20100801

• Study of benzo[a]phenazine 7,12-dioxide as selective hypoxic cytotoxin-scaffold. Identification of aerobic-antitumoral activity through DNA fragmentation.

  Bioorganic & medicinal chemistry 20100615

• A case report of the second de novo acute myeloid leukemia (AML) following allogeneic stem cell transplantation in a patient with the first AML.

  The Korean journal of internal medicine 20100301

• Assisted sonodynamic damage of bovine serum albumin by metronidazole under ultrasonic irradiation combined with photosensitive antitumor drug-Amsacrine.

  Journal of photochemistry and photobiology. B, Biology 20100121

• Synthesis and antiproliferative evaluations of certain 2-phenylvinylquinoline (2-styrylquinoline) and 2-furanylvinylquinoline derivatives.

  Bioorganic & medicinal chemistry 20100101

• Fluorescence-tracking of activation gating in human ERG channels reveals rapid S4 movement and slow pore opening.

  PloS one 20100101

• Idiopathic hyperammonemia after chemotherapy with vinorelbine, topotecan, and cisplatin in a patient with acute lymphocytic leukemia.

  Hematology/oncology and stem cell therapy 20100101

• Historical development of basic concepts of Ayurveda from Veda up to Samhita.

  Ayu 20100101

• A clinical study of Nirgundi Ghana Vati and Matra Basti in the management of Gridhrasi with special reference to sciatica.

  Ayu 20100101

• Randomized placebo-controlled trial of Mustadi Ghanavati in hyperlipidemia.

  Ayu 20100101

• Citrulline as a marker for chemotherapy induced mucosal barrier injury in pediatric patients.

  Pediatric blood & cancer 20091215

• Synthesis of 9-anilinoacridine triazines as new class of hybrid antimalarial agents.

  Bioorganic & medicinal chemistry letters 20091215

• Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia.

  Bone marrow transplantation 20091201

• Population dynamics of methicillin-susceptible and -resistant Staphylococcus aureus in remote communities.

  The Journal of antimicrobial chemotherapy 20091001

• Partial purification and characterization of Trichomonas vaginalis DNA topoisomerase II.

  The Southeast Asian journal of tropical medicine and public health 20090901

• Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical Significance.

  Current cardiology reviews 20090801

• Synthesis and in vitro cytotoxicity of 9-anilinoacridines bearing N-mustard residue on both anilino and acridine rings.

  European journal of medicinal chemistry 20090701

• DNA-targeting pyrroloquinoline-linked butenone and chalcones: synthesis and biological evaluation.

  European journal of medicinal chemistry 20090701

• Genistein inhibition of topoisomerase IIalpha expression participated by Sp1 and Sp3 in HeLa cell.

  International journal of molecular sciences 20090701

• Involvement of nucleotide excision and mismatch repair mechanisms in double strand break repair.

  Current genomics 20090601

• Treatment-subgroup interaction: an example from a published, phase II clinical trial.

  Contemporary clinical trials 20090501

• Synthesis, cytotoxic activity, DNA topoisomerase-II inhibition, molecular modeling and structure-activity relationship of 9-anilinothiazolo[5,4-b]quinoline derivatives.

  Bioorganic & medicinal chemistry 20090501

• Search for MDR modulators: design, syntheses and evaluations of N-substituted acridones for interactions with p-glycoprotein and Mg2+.

  Bioorganic & medicinal chemistry 20090315

• Activated toxicity of diesel particulate extract by ultraviolet a radiation in mammalian cells: role of singlet oxygen.

  Environmental health perspectives 20090301

• Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery.

  International journal of pharmaceutics 20090209

• Synthesis and antitumor activity of novel amsacrine analogs: the critical role of the acridine moiety in determining their biological activity.

  Bioorganic & medicinal chemistry 20090115

• Novel acridine-based compounds that exhibit an anti-pancreatic cancer activity are catalytic inhibitors of human topoisomerase II.

  European journal of pharmacology 20090114

• Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study.

  BMC cancer 20090101

• Altering chemosensitivity by modulating translation elongation.

  PloS one 20090101

• Evaluation of molecular descriptors for antitumor drugs with respect to noncovalent binding to DNA and antiproliferative activity.

  BMC pharmacology 20090101

• Text mining and manual curation of chemical-gene-disease networks for the comparative toxicogenomics database (CTD).

  BMC bioinformatics 20090101

• The SNF2-family member Fun30 promotes gene silencing in heterochromatic loci.

  PloS one 20090101

• Zolpidem, a clinical hypnotic that affects electronic transfer, alters synaptic activity through potential GABA receptors in the nervous system without significant free radical generation.

  Oxidative medicine and cellular longevity 20090101

• Novel imidazo[1,2-a]naphthyridinic systems (part 1): synthesis, antiproliferative and DNA-intercalating activities.

  European journal of medicinal chemistry 20081101

• Isolation and characterization of mAMSA-hypersensitive mutants. Cytotoxicity of Top2 covalent complexes containing DNA single strand breaks.

  The Journal of biological chemistry 20081024

• Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.

  Journal of medicinal chemistry 20081009

• An experimental and theoretical study of dipole moments of N-[4-(9-acridinylamino)-3-methoxyphenyl]methanesulfonamide.

  Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20080901

• A role for topoisomerase II alpha in the formation of radiation-induced chromatid breaks.

  British journal of cancer 20080819

• Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma.

  Bioorganic & medicinal chemistry 20080815

• Synthesis and biological activity of stable and potent antitumor agents, aniline nitrogen mustards linked to 9-anilinoacridines via a urea linkage.

  Bioorganic & medicinal chemistry 20080515

• Is MutaMouse insensitive to clastogens?

  Mutation research 20080430

• Detecting genotoxic effects of potential clastogens: an in vivo study using the transgenic lacZ plasmid and the MutaMouse model.

  Mutation research 20080430

• DNA threading bis(9-aminoacridine-4-carboxamides): effects of piperidine sidechains on DNA binding, cytotoxicity and cell cycle arrest.

  Bioorganic & medicinal chemistry 20080415

• Using 3'-bridging phosphorothiolates to isolate the forward DNA cleavage reaction of human topoisomerase IIalpha.

  Biochemistry 20080401

• The chemotherapeutic agents nocodazole and amsacrine cause meiotic delay and non-disjunction in spermatocytes of mice.

  Mutation research 20080312

• Amsacrine containing induction therapy in elderly AML patients: comparison to standard induction regimens in a matched-pair analysis.

  Leukemia research 20080301

• Synthesis and biological evaluation of pyrroloiminoquinone derivatives.

  Bioorganic & medicinal chemistry 20080301

• Synthesis and antiproliferative activity of benzyl and phenethyl analogs of makaluvamines.

  Bioorganic & medicinal chemistry 20080301

• Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia.

  Leukemia & lymphoma 20080301

• Antitumor polycyclic acridines. 20. Search for DNA quadruplex binding selectivity in a series of 8,13-dimethylquino[4,3,2-kl]acridinium salts: telomere-targeted agents.

  Journal of medicinal chemistry 20080227

• Discovery of a new anilino-3H-pyrrolo[3,2-f]quinoline derivative as potential anti-cancer agent.

  European journal of medicinal chemistry 20080201

• Synthesis, cytotoxic evaluation, and DNA binding of novel thiazolo[5,4-b]quinoline derivatives.

  Bioorganic & medicinal chemistry 20080201

• Development and validation of bioanalytical method for the determination of asulacrine in plasma by liquid chromatography.

  Journal of pharmaceutical and biomedical analysis 20080122

• Addition of PTK787/ZK 222584 can lower the dosage of amsacrine to achieve equal amounts of acute myeloid leukemia cell death.

  Anti-cancer drugs 20080101

• Anticancer compounds as leishmanicidal drugs: challenges in chemotherapy and future perspectives.

  Current medicinal chemistry 20080101

• The impact of the human DNA topoisomerase II C-terminal domain on activity.

  PloS one 20080101

• A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial.

  BMC cancer 20080101

• [A case of unclassified B-cell lymphosarcoma].

  Terapevticheskii arkhiv 20080101

• Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells.

  Journal of natural products 20071201

• 3,5-bis(3'-indolyl)pyrazoles, analogues of marine alkaloid nortopsentin: synthesis and antitumor properties.

  Bioorganic & medicinal chemistry letters 20071115

• The DNA-binding epidermal growth factor-receptor inhibitor PD153035 and other DNA-intercalating cytotoxic drugs reactivate the expression of the retinoic acid receptor-beta tumor-suppressor gene in breast cancer cells.

  Differentiation; research in biological diversity 20071101

• Interactions between antiplasmodial 3,6-diamino-1'-dimethyl-9-anilinoacridine and hematin and concanamycin A.

  The Southeast Asian journal of tropical medicine and public health 20071101

• Decitabine in the treatment of myelodysplastic syndromes.

  Therapeutics and clinical risk management 20071001

• Generation and identification of reactive metabolites by electrochemistry and immobilized enzymes coupled on-line to liquid chromatography/mass spectrometry.

  Analytical chemistry 20070901

• Human p53 is inhibited by glutathionylation of cysteines present in the proximal DNA-binding domain during oxidative stress.

  Biochemistry 20070703

• Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome.

  Biochemical pharmacology 20070615

• Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs.

  Cancer research 20070615

• Characterization of DNA reactive and non-DNA reactive anticancer drugs by gene expression profiling.

  Mutation research 20070601

• Analogs of the marine alkaloid makaluvamines: synthesis, topoisomerase II inhibition, and anticancer activity.

  Bioorganic & medicinal chemistry letters 20070515

• The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients.

  American journal of hematology 20070501

• Differential selection of acridine resistance mutations in human DNA topoisomerase IIbeta is dependent on the acridine structure.

  Molecular pharmacology 20070401

• Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol.

  Pediatric blood & cancer 20070301

• Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group.

  Leukemia 20070301

• Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.

  Haematologica 20070301

• The decatenation checkpoint.

  British journal of cancer 20070129

• Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells.

  PloS one 20070101

• Synthesis and structure-activity studies of peptide-acridine/acridone conjugates.

  Current medicinal chemistry 20070101

• Topoisomerase II and tubulin inhibitors both induce the formation of apoptotic topoisomerase I cleavage complexes.

  Molecular cancer therapeutics 20061201

• Primary invasive aspergillosis of the digestive tract: report of two cases and review of the literature.

  Infection 20061201

• New methods for direct delivery of chemotherapy for treating brain tumors.

  The Yale journal of biology and medicine 20061201

• Epidermal growth factor induction of resistance to topoisomerase II toxins in human squamous carcinoma A431 cells.

  Oncology reports 20061001

• Synthesis and evaluation of acridine- and acridone-based anti-herpes agents with topoisomerase activity.

  Bioorganic & medicinal chemistry 20060815

• Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation.

  Blood 20060801

• AClAP, Autonomous hierarchical agglomerative Cluster Analysis based protocol to partition conformational datasets.

  Bioinformatics (Oxford, England) 20060715

• Digitoxin, at concentrations commonly found in the plasma of cardiac patients, antagonizes etoposide and idarubicin activity in K562 leukemia cells.

  Leukemia research 20060701

• Bioactive principles in the bark of Pilidiostigma tropicum.

  Journal of molecular modeling 20060701

• Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.

  Molecular cancer therapeutics 20060601

• A novel interaction [corrected] of nucleolin with Rad51.

  Biochemical and biophysical research communications 20060526

• Treatment of relapsed acute myeloid leukaemia.

  Reviews on recent clinical trials 20060501

• Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials.

  British journal of haematology 20060301

• Adaphostin and other anticancer drugs quench the fluorescence of mitochondrial potential probes.

  Cell death and differentiation 20060101

• Mutation P732L in human DNA topoisomerase IIbeta abolishes DNA cleavage in the presence of calcium and confers drug resistance.

  Molecular pharmacology 20060101

• mAMSA resistant human topoisomerase IIbeta mutation G465D has reduced ATP hydrolysis activity.

  Nucleic acids research 20060101

• Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia.

  BMC cancer 20060101

• Zygomycosis in the immunocompromised patient: a case report.

  Acta bio-medica : Atenei Parmensis 20060101

• Successful pulmonary administration of activated recombinant factor VII in diffuse alveolar hemorrhage.

  Critical care (London, England) 20060101

• Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit--multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group.

  Leukemia 20051201

• Type II topoisomerase activities in both the G1 and G2/M phases of the dinoflagellate cell cycle.

  Chromosoma 20051201

• Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.

  Haematologica 20051201

• The DNA demethylating 5-azaC induces endoreduplication in cultured Chinese hamster cells.

  Mutation research 20051015

• Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.

  Japanese journal of clinical oncology 20051001

• Synthesis of a novel series of 2-methylsulfanyl fatty acids and their toxicity on the human K-562 and U-937 leukemia cell lines.

  Lipids 20051001

• In vitro activity of the flt3-inhibitor su5614 and standard cytotoxic agents in tumour cells from patients with wild type and mutated flt3 acute myeloid leukaemia.

  Leukemia research 20050901

• Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050820

• Inhibition of human CYP1A2 oxidation of 5,6-dimethyl-xanthenone-4-acetic acid by acridines: a molecular modelling study.

  Clinical and experimental pharmacology & physiology 20050801

• Acridine derivatives activate p53 and induce tumor cell death through Bax.

  Cancer biology & therapy 20050801

• BAVC regimen and autologous bone marrow transplantation for APL patients in second molecular remission: updated results.

  Bone marrow transplantation 20050701

• Highly sensitive analysis of the anti-tumor agent 1-[4-(furo[2,3-b]-quinolin-4-ylamino)phenyl]ethanone in rat plasma by high-performance liquid chromatography using electrochemical detection.

  Journal of pharmaceutical and biomedical analysis 20050701

• Potent antitumor 9-anilinoacridines bearing an alkylating N-mustard residue on the anilino ring: synthesis and biological activity.

  Bioorganic & medicinal chemistry 20050602

• Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation.

  Leukemia & lymphoma 20050601

• E1A specifically enhances sensitivity to topoisomerase IIalpha targeting anticancer drug by up-regulating the promoter activity.

  Molecular cancer research : MCR 20050501

• [Disseminated cutaneous and visceral fusariosis in an aplastic patient: an unusual digestive entry].

  Annales de dermatologie et de venereologie 20050301

• Random mutagenesis of the B'A' core domain of yeast DNA topoisomerase II and large-scale screens of mutants resistant to the anticancer drug etoposide.

  Biochemical and biophysical research communications 20050211

• Synthesis, antitumour activity and structure-activity relationships of 5H-benzo[b]carbazoles.

  Bioorganic & medicinal chemistry 20050201

• Induction chemotherapy for acute myelogenous leukemia.

  Current hematology reports 20050101

• Synthesis and antitumor activity of sulfur-containing 9-anilinoacridines.

  Molecular pharmaceutics 20050101

• Cardiotoxicity of cancer chemotherapy: implications for children.

  Paediatric drugs 20050101

• Usefulness of PKH fluorescent labelling to study leukemic cell proliferation with various cytostatic drugs or acetyl tetrapeptide--AcSDKP.

  BMC cancer 20050101

• Translocation t(12;21) is related to in vitro cellular drug sensitivity to doxorubicin and etoposide in childhood acute lymphoblastic leukemia.

  Blood 20041015

• Establishment and characterisation of a human carcinoma cell line with acquired resistance to Aplidin.

  British journal of cancer 20041004

• The antitumor triazoloacridone C-1305 is a topoisomerase II poison with unusual properties.

  Molecular pharmacology 20041001

• Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation.

  Bioorganic & medicinal chemistry letters 20040920

• Mutation E522K in human DNA topoisomerase IIbeta confers resistance to methyl N-(4'-(9-acridinylamino)-phenyl)carbamate hydrochloride and methyl N-(4'-(9-acridinylamino)-3-methoxy-phenyl) methane sulfonamide but hypersensitivity to etoposide.

  Molecular pharmacology 20040901

• Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.

  Annals of hematology 20040801

• Dissecting the cell-killing mechanism of the topoisomerase II-targeting drug ICRF-193.

  The Journal of biological chemistry 20040702

• Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout cells to antitumor triazoloacridone C-1305 is associated with permanent G2 cell cycle arrest.

  Cancer research 20040701

• A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia.

  Blood 20040615

• Risk-adapted induction and consolidation therapy in adults with de novo AML aged </= 60 years: results of a prospective multicenter trial.

  Annals of hematology 20040601

• Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action.

  British journal of pharmacology 20040601

• Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.

  Biochemical and biophysical research communications 20040319

• Structure-activity relationships for the 9-(pyridin-2'-yl)- aminoacridines.

  Molecules (Basel, Switzerland) 20040227

• Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.

  Cancer chemotherapy and pharmacology 20040201

• Comparison of BAVC to BuCy regimens in autologous stem cell transplantation for adult patients with acute myeloid leukemia.

  Haematologica 20040101

• Topoisomerase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells.

  Molecular cancer research : MCR 20040101

• Rescue therapy combining intermediate-dose cytarabine with amsacrine and etoposide in relapsed adult acute lymphoblastic leukemia.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Maintenance therapy in childhood acute myeloid leukemia.

  Annals of hematology 20040101

• Investigations into the biological relevance of in vitro clastogenic and aneugenic activity.

  Cytogenetic and genome research 20040101

• Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.

  BMC pharmacology 20040101

• Bisintercalating threading diacridines: relationships between DNA binding, cytotoxicity, and cell cycle arrest.

  Journal of medicinal chemistry 20031218

• A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia.

  Blood 20031215

• Mechanisms of action of DNA intercalating acridine-based drugs: how important are contributions from electron transfer and oxidative stress?

  Current medicinal chemistry 20031201

• More efficient mobilisation of peripheral blood stem cells with HiDAC+AMSA+G-CSF than with mini-ICE+G-CSF in patients with AML.

  Bone marrow transplantation 20031201

• [Topotecan-based combined chemotherapy for refractory or relapsed hematologic malignancies].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20031101

• Stem cell transplantation after salvage therapy with high-dose cytarabine and amsacrine in adults with high-risk leukaemia.

  Bone marrow transplantation 20030801

• Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia.

  British journal of haematology 20030801

• Antitumor triptycene bisquinones: a novel synthetic class of dual inhibitors of DNA topoisomerase I and II activities.

  Anti-cancer drugs 20030801

• Acute pericarditis and pleural effusion complicating cytarabine chemotherapy.

  Onkologie 20030801

• A preliminary evaluation of a new selective agar supplemented with desferrioxamine for detection of methicillin-resistant Staphylococcus aureus.

  The Journal of hospital infection 20030701

• In vitro chemosensitivity testing of selected myeloid cells in acute myeloid leukemia.

  Leukemia & lymphoma 20030501

• Phosphorylation of serine 1106 in the catalytic domain of topoisomerase II alpha regulates enzymatic activity and drug sensitivity.

  The Journal of biological chemistry 20030411

• Amino acid substitutions at position 43 of NaeI endonuclease. Evidence for changes in NaeI structure.

  The Journal of biological chemistry 20030314

• Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines.

  Journal of medicinal chemistry 20030313

• Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.

  Leukemia research 20030301

• Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission.

  Blood 20030215

• Free radical scavengers can differentially modulate the genotoxicity of amsacrine in normal and cancer cells.

  Mutation research 20030205

• Crystallization and preliminary X-ray analysis of anti-cancer agent 3-(9-acridinylamino)-5-(hydroxymethyl)aniline complexed with the DNA hexamer d(CGTACG)2.

  Biochimica et biophysica acta 20030103

• [Effect of etoposide and amsacrine on mitotic progression of GM-130 and Hep-2 cell lines. The flow cytometry assay].

  Tsitologiia 20030101

• Dinucleoside monophosphates containing AZT and 1-methyladenosine or 7-methylguanosine.

  Nucleosides, nucleotides & nucleic acids 20030101

• Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.

  Bone marrow transplantation 20021201

• Synthesis and antiinflammatory evaluation of 9-anilinoacridine and 9-phenoxyacridine derivatives.

  Journal of medicinal chemistry 20021010

• Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I.

  The Biochemical journal 20020901

• Point of attachment and sequence of immobilized peptide-acridine conjugates control affinity for nucleic acids.

  Journal of the American Chemical Society 20020724

• Tetrakis-acridinyl peptide: a novel fluorometric reagent for nucleic acid analysis based on the fluorescence dequenching upon DNA binding.

  The Analyst 20020701

• A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents.

  Biochemistry 20020625

• Increased expression of beta 2-microglobulin in multidrug-resistant tumour cells.

  British journal of cancer 20020617

• Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucámie Aiqüe Myéloïde Enfant.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020615

• High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter.

  Carcinogenesis 20020601

• Cytotoxicity of rhein, the active metabolite of sennoside laxatives, is reduced by multidrug resistance-associated protein 1.

  British journal of cancer 20020506

• Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.

  The Journal of biological chemistry 20020419

• The modulation of the DNA-damaging effect of polycyclic aromatic agents by xanthines. Part I. Reduction of cytostatic effects of quinacrine mustard by caffeine.

  Biochemical pharmacology 20020215

• Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours.

  British journal of cancer 20020212

• Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.

  Blood 20020101

• Mitotic arrest induced by XK469, a novel antitumor agent, is correlated with the inhibition of cyclin B1 ubiquitination.

  International journal of cancer 20020101

• A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation.

  Cancer chemotherapy and pharmacology 20020101

• A rare case of adenoviral fulminant hepatic necrosis after chemotherapy.

  Pediatric hematology and oncology 20020101

• Compatibility and stability of 5-HT3 receptor antagonists: a pharmacology review.

  Oncology nursing forum 20020101

• Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor.

  Molecular cancer therapeutics 20020101

• Partial purification of mitochondrial DNA topoisomerase II from Plasmodium falciparum and its sensitivity to inhibitors.

  The Southeast Asian journal of tropical medicine and public health 20011201

• Design of new anti-cancer agents based on topoisomerase poisons targeted to specific DNA sequences.

  Current medicinal chemistry. Anti-cancer agents 20011101

• Catalytic inhibition of human DNA topoisomerase IIalpha by hypericin, a naphthodianthrone from St. John's wort (Hypericum perforatum).

  Biochemical pharmacology 20011015

• Incidence of mutation and deletion in topoisomerase II alpha mRNA of etoposide and mAMSA-resistant cell lines.

  Japanese journal of cancer research : Gann 20011001

• Co-amplification of dhfr and a homologue of hmsh3 in a Chinese hamster methotrexate-resistant cell line correlates with resistance to a range of chemotherapeutic drugs.

  Cancer chemotherapy and pharmacology 20011001

• FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.

  European journal of haematology 20011001

• Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta.

  British journal of cancer 20010901

• Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.

  Japanese journal of cancer research : Gann 20010901

• Suppression of c-myc expression and c-Myc function in response to sustained DNA damage in MCF-7 breast tumor cells.

  Biochemical pharmacology 20010901

• Amsacrine and cisplatin in poor prognosis patients with metastatic transitional cell carcinoma of the urothelium: a phase-II study.

  European urology 20010901

• Reciprocal control of expression of mRNAs for osteoclast differentiation factor and OPG in osteogenic stromal cells by genistein: evidence for the involvement of topoisomerase II in osteoclastogenesis.

  Endocrinology 20010801

• Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes.

  British journal of clinical pharmacology 20010801

• Atypical multidrug resistance may be associated with catalytically active mutants of human DNA topoisomerase II alpha.

  Gene 20010711

• Novel pyrrolo[3,2-f]quinolines: synthesis and antiproliferative activity.

  Bioorganic & medicinal chemistry 20010701

• Expression of drug resistance genes in VP-16 and mAMSA-selected human carcinoma cells.

  Japanese journal of cancer research : Gann 20010701

• Hypophosphorylation of topoisomerase IIalpha in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation.

  Japanese journal of cancer research : Gann 20010701

• Synthesis and cytotoxic activity of 7-oxo-7H-dibenz[f,ij]isoquinoline and 7-oxo-7H-benzo[e]perimidine derivatives.

  Journal of medicinal chemistry 20010607

• Atp-bound topoisomerase ii as a target for antitumor drugs.

  The Journal of biological chemistry 20010511

• Repair of topoisomerase-mediated DNA damage in bacteriophage T4.

  Genetics 20010501

• Improved efficiency of remission induction facilitates autologous BMT harvesting and improves overall survival in adults with AML: 108 patients treated at a single institution.

  Bone marrow transplantation 20010501

• Selection of an unnatural peptide library for dsDNA binding.

  Current medicinal chemistry 20010401

• A phase I trial of amsalog (CI-921) administered by intravenous infusion using a 5-day schedule.

  Cancer chemotherapy and pharmacology 20010401

• Paclitaxel sensitization of multidrug-resistant cells to chemotherapy is independent of the cell cycle.

  Cytometry 20010301

• Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia.

  European journal of haematology 20010301

• Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon.

  American journal of clinical pathology 20010201

• Analysis of cleavage complexes using reactive inhibitor derivatives.

  Methods in molecular biology (Clifton, N.J.) 20010101

• Cell-cycle analysis of drug-treated cells.

  Methods in molecular biology (Clifton, N.J.) 20010101

• Targeting DNA through-covalent interactions of reversible binding drugs.

  Methods in enzymology 20010101

• Inhibition of apoptotic proteins causes multidrug resistance in renal carcinoma cells.

  Anticancer research 20010101

• DNA binding properties of the indolocarbazole antitumor drug NB-506.

  Anti-cancer drug design 20010101

• Mutations at arg486 and glu571 in human topoisomerase IIalpha confer resistance to amsacrine: relevance for antitumor drug resistance in human cells.

  Molecular pharmacology 20000401

• Werner's syndrome lymphoblastoid cells are hypersensitive to topoisomerase II inhibitors in the G2 phase of the cell cycle.

  Mutation research 20000320

• 1,3-Dihydroxyacridone derivatives as inhibitors of herpes virus replication.

  Antiviral research 20000201

• Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs.

  Cancer chemotherapy and pharmacology 20000101

• [Studies on programmed cell death induced by amsacrine and expression of bcl-2 in leukemia cell lines].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 19970901

• Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.

  Biochemistry 19970311

• [Venous protection of acute leukemia treatment with amsacrine].

  Zhonghua hu li za zhi = Chinese journal of nursing 19960901

• Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma.

  Blood 19960201

• Induction of small intestinal adenocarcinomas in Wistar rats administered amsacrine.

  Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 19941001

• Activity of topoisomerase inhibitors against Pneumocystis carinii in vitro and in an inoculated mouse model.

  Antimicrobial agents and chemotherapy 19930701

• Apoptosis of S-phase HL-60 cells induced by DNA topoisomerase inhibitors: detection of DNA strand breaks by flow cytometry using the in situ nick translation assay.

  Toxicology letters 19930401

• Inhibitors of human immunodeficiency virus integrase.

  Proceedings of the National Academy of Sciences of the United States of America 19930315

• Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia.

  Cancer 19910915

• Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II.

  Cancer research 19910901

• Daunorubicin, amsacrine, and sinus arrest.

  The Western journal of medicine 19910401

• Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.

  European journal of cancer (Oxford, England : 1990) 19910101

• Preventing amsacrine-induced cardiac arrhythmias.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 19871201

• Treatment of acute leukaemia with m-AMSA in combination with cytosine arabinoside.

  Cancer chemotherapy and pharmacology 19860101

• Sequentially administered 5-azacitidine and amsacrine in refractory adult acute leukemia: a phase I-II trial of the Southeastern Cancer Study Group.

  Cancer treatment reports 19850101

• Prevention of amsacrine-induced phlebitis with heparin.

  Clinical pharmacy 19820101